

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of October 2012

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
FORM 20-F  X  FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: October 31, 2012

By: /s/ "Darrell Brookstein"  
Darrell Brookstein  
Director

**Exhibits:**

- 99.1 News Release dated October 30, 2012**
- 99.2 News Release dated October 31, 2012**

## ACQUISITION OF SHARES OF STELLAR

PORT HUENEME, CA (October 30, 2012) -- Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) announces that, further to its press release dated October 26, 2012, Ernesto Echavarria acquired ownership and control of 3,000,000 units ("Units") in the capital of Stellar at a price of CDN \$0.25 per unit. Each Unit is comprised of one common share and one transferable share purchase warrant, with each warrant exercisable into one common share of the Company on or before October 25, 2015 at an exercise price of CDN \$0.40 per share. These holdings represent approximately 6.1% of the total issued and outstanding common shares of the Company as of October 25, 2012, or 11.5% calculated on a partially diluted basis assuming exercise of the warrants.

Following the acquisition, Mr. Echavarria owns and controls 8,420,833 common shares and 5,683,333 share purchase warrants of the Company, representing approximately 17.0% of the issued and outstanding common shares of the Company, or 25.6% on a partially diluted basis, assuming exercise of the warrants and that no other common shares are issued by the Company. Mr. Ernesto has filed an undertaking with the TSX Venture Exchange that he will not exercise any warrants, if doing so will result in him becoming a control person of Stellar.

Mr. Echavarria acquired the Units for investment purposes. He has no current intention to obtain beneficial ownership of additional securities of the Company, however he may, in the ordinary course of business, acquire additional securities of the Company for investment purposes.

About Stellar Biotechnologies, Inc. ([www.StellarBiotech.com](http://www.StellarBiotech.com))

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of [http://stellarbiotechnologies.com/investors/news\\_releases/](http://stellarbiotechnologies.com/investors/news_releases/)

Contact:

Darrell Brookstein  
Executive VP, Corporate Development & Finance  
[dbrookstein@stellarbiotech.com](mailto:dbrookstein@stellarbiotech.com)

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

## **Stellar Biotechnologies to Present at SoCalBio Investor Conference in Los Angeles on November 7th, 2012**

PORT HUENEME, CA (October 31, 2012) -- Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), today announced that the Company will present at the 14th Annual SoCalBio Investor Conference in Los Angeles.

Mr. Darrell Brookstein, Stellar's Executive VP, Corporate Development & Finance, will be presenting at the Omni Hotel in Los Angeles on November 7th, 2012. Mr. Brookstein will discuss the Company's unique business model stemmed from being the only renewable supplier of KLH for large drug producers. Details of the Company's current growth initiatives for 2013 will also be provided.

"This is a terrific opportunity for Stellar to introduce our story to a broad group of institutional and retail investors. We have made significant progress across all facets of our business and look forward to sharing more details with the investment community at large in the coming weeks and months," said Executive VP, Darrell Brookstein.

The SoCalBio Investor Conference and Exhibition is a one-day conference organized by the Southern California Biomedical Council to showcase the strength and future of the bioscience industry in Los Angeles, Orange County and neighboring communities. For more information, please visit the conference website at [http://www.socalbio.org/SocalBio\\_2012/home\\_2012.htm](http://www.socalbio.org/SocalBio_2012/home_2012.htm)

About Stellar Biotechnologies, Inc. ([www.StellarBiotech.com](http://www.StellarBiotech.com))

Stellar Biotechnologies, Inc. (TSX-V: KLH) (OTC: SBOTF) (Frankfurt: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of [http://stellariotechnologies.com/investors/news\\_releases/](http://stellariotechnologies.com/investors/news_releases/)

### Contacts:

Stellar Biotechnologies, Inc.

Darrell Brookstein  
Executive VP, Corporate Development and Finance  
Phone: 805 488 2800  
Email: [dbrookstein@stellariotech.com](mailto:dbrookstein@stellariotech.com)

### Investor Relations:

MZ Group  
Mark A. McPartland  
Senior Vice President  
Phone: 1 212-301-7130  
Email: [markmcp@mzgroup.us](mailto:markmcp@mzgroup.us)  
Web: [www.mzgroup.us](http://www.mzgroup.us)

### Forward-Looking Statements

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

